PMID- 26949133
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20220408
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 165
DP  - 2016 May
TI  - Photoactivated Chromophore for Moderate to Severe Infectious Keratitis as an 
      Adjunct Therapy: A Randomized Controlled Trial.
PG  - 94-9
LID - S0002-9394(16)30080-0 [pii]
LID - 10.1016/j.ajo.2016.02.030 [doi]
AB  - PURPOSE: To evaluate the efficacy of photoactivated chromophore for infectious 
      keratitis (PACK-CXL) in the treatment of patients with moderate to severe 
      infectious keratitis as adjunct therapy to the topical medication treatment. 
      DESIGN: Randomized clinical trial. METHODS: Thirty eyes from 30 patients with 
      moderate to severe infectious keratitis were randomized to receive either 
      standard treatment plus PACK-CXL (n = 15) or standard treatment alone (control 
      group, n = 15). The primary outcome was the sizes of stromal infiltrates measured 
      on slit-lamp photographs 30 days after treatment. The secondary outcomes were the 
      sizes of epithelial defects, the complication rates, and best pinhole-corrected 
      visual acuity (BPVA). RESULTS: The median (interquartile range [IQR]) sizes of 
      stromal infiltrates at day 30 were 5.0 mm(2) (0-23.0 mm(2)) in the PACK-CXL group 
      and 10.6 mm(2) (1.1-16.3 mm(2)) in the control group (median difference 0, 95% 
      CI -7.0 to 0, P = .66). The median (IQR) sizes of epithelial defects were 
      0.7 mm(2) (0-6.3 mm(2)) and 4.6 mm(2) (0-10.2 mm(2)) in the PACK-CXL group and 
      control group, respectively (median difference -3.0, 95% CI -0.8 to 0, P = .41). 
      The complication rates and BPVA after treatment were comparable between groups. 
      CONCLUSIONS: Standard treatment combined with PACK-CXL did not provide any 
      advantageous effect over standard treatment alone in moderate to severe 
      infectious keratitis over a 30-day period.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kasetsuwan, Ngamjit
AU  - Kasetsuwan N
AD  - Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and 
      King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
FAU - Reinprayoon, Usanee
AU  - Reinprayoon U
AD  - Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and 
      King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
FAU - Satitpitakul, Vannarut
AU  - Satitpitakul V
AD  - Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, and 
      King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Electronic address: 
      vannaruts@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160303
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Photosensitizing Agents)
RN  - 84319SGC3C (Amikacin)
RN  - 9007-34-5 (Collagen)
RN  - IHS69L0Y4T (Cefazolin)
RN  - TLM2976OFR (Riboflavin)
SB  - IM
CIN - Am J Ophthalmol. 2016 Aug;168:294-295. PMID: 27292530
CIN - Am J Ophthalmol. 2016 Aug;168:293-294. PMID: 27292531
MH  - Administration, Topical
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amikacin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Cefazolin/therapeutic use
MH  - Collagen/metabolism
MH  - Combined Modality Therapy
MH  - Corneal Stroma/metabolism
MH  - Corneal Ulcer/*drug therapy/metabolism/microbiology
MH  - *Cross-Linking Reagents
MH  - Eye Infections, Bacterial/*drug therapy/metabolism/microbiology
MH  - Eye Infections, Fungal/*drug therapy/metabolism/microbiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/*therapeutic use
MH  - Riboflavin/therapeutic use
MH  - Ultraviolet Rays
MH  - Visual Acuity
MH  - Young Adult
EDAT- 2016/03/08 06:00
MHDA- 2017/04/28 06:00
CRDT- 2016/03/08 06:00
PHST- 2015/10/29 00:00 [received]
PHST- 2016/02/23 00:00 [revised]
PHST- 2016/02/24 00:00 [accepted]
PHST- 2016/03/08 06:00 [entrez]
PHST- 2016/03/08 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
AID - S0002-9394(16)30080-0 [pii]
AID - 10.1016/j.ajo.2016.02.030 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2016 May;165:94-9. doi: 10.1016/j.ajo.2016.02.030. Epub 2016 Mar 
      3.